Macquarie Group
JNCE

Macquarie Group’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Macquarie Group’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,100
Closed -$7K – 2146
2018
Q4 		$7K Buy
+2,100
New +$9.81K ﹤0.01% 2020
2018
Q1 		– Sell
-600
Closed -$8K – 2435
2017
Q4 		$8K Sell
600
-7,368
-92% -$108K ﹤0.01% 2320
2017
Q3 		$124K Buy
+7,968
New +$113K ﹤0.01% 1870

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Macquarie Group's JNCE Position: Q1 2019 in Review

Macquarie Group sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2019, closing a stake of 2,100 shares — an estimated $7K sold.

Macquarie Group first reported a position in JNCE in Q3 2017 and held it in 3 quarters. The position peaked at $124K in Q3 2017. 80 funds tracked by Wall St. Rank hold JNCE as of Q1 2019.

  • Macquarie Group reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Macquarie Group sold 2,100 Jounce Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $7K.
  • Macquarie Group first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2017 and held it in 3 quarters.
  • Macquarie Group's Jounce Therapeutics, Inc. Common Stock position peaked at $124K in Q3 2017.
  • 80 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Macquarie Group's 13F filing for Q1 2019, filed 15 May 2019.